argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-06-06 08:31 |
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in…
|
English | 91.4 KB | ||
| 2018-05-09 07:21 |
argenx reports first quarter 2018 financial results and provides business update
|
English | 26.8 KB | ||
| 2018-05-08 10:42 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 102.9 KB | ||
| 2018-04-24 07:34 |
argenx to present complete data from the Phase 2 proof-of-concept trial of efga…
|
English | 60.4 KB | ||
| 2018-04-12 07:35 |
argenx to receive third preclinical milestone payment from collaboration with L…
|
English | 152.2 KB | ||
| 2018-04-09 08:34 |
argenx appoints Keith Woods as Chief Operating Officer
|
English | 93.0 KB | ||
| 2018-03-27 08:56 | English | 9.0 MB | |||
| 2018-03-26 08:34 |
argenx announces orphan drug designation for ARGX-113 for the treatment of myas…
|
English | 14.6 KB | ||
| 2018-03-16 07:30 |
argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies
|
English | 208.2 KB | ||
| 2018-02-22 07:18 |
argenx to host conference call & webcast to report fourth quarter business upda…
|
English | 90.6 KB | ||
| 2017-12-19 07:29 |
argenx announces closing of U.S. public offering for gross proceeds of approxim…
|
English | 155.4 KB | ||
| 2017-12-14 07:21 |
argenx raises approximately $231 million in gross proceeds in an upsized U.S. p…
|
English | 156.0 KB | ||
| 2017-12-12 07:56 |
argenx announces launch of proposed public offering in the United States
|
English | 78.2 KB | ||
| 2017-12-11 09:38 |
argenx reports positive topline results from Phase 2 proof-of-concept trial of …
|
English | 114.4 KB | ||
| 2017-12-11 09:20 |
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Mye…
|
English | 18.5 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
